523 related articles for article (PubMed ID: 29712435)
21. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
22. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D; Macdougall IC
Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
[TBL] [Abstract][Full Text] [Related]
23. Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
Li L; Nakano D; Zhang A; Kittikulsuth W; Morisawa N; Ohsaki H; Suzuki N; Yamamoto M; Nishiyama A
J Pharmacol Sci; 2020 Dec; 144(4):229-236. PubMed ID: 33070842
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
Kaplan JM; Sharma N; Dikdan S
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
[TBL] [Abstract][Full Text] [Related]
25. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia.
Yu Y; Yang F; Yu Q; Liu S; Wu C; Su K; Yang L; Bao X; Li Z; Li X; Zhang X
J Med Chem; 2021 Dec; 64(23):17384-17402. PubMed ID: 34709043
[TBL] [Abstract][Full Text] [Related]
27. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
[TBL] [Abstract][Full Text] [Related]
28. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
Kato S; Takahashi T; Miyata N; Roman RJ
J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
[TBL] [Abstract][Full Text] [Related]
29. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
30. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
Böttcher M; Lentini S; Arens ER; Kaiser A; van der Mey D; Thuss U; Kubitza D; Wensing G
Br J Clin Pharmacol; 2018 Jul; 84(7):1557-1565. PubMed ID: 29575006
[TBL] [Abstract][Full Text] [Related]
31. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Sugahara M; Tanaka T; Nangaku M
Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
[TBL] [Abstract][Full Text] [Related]
32. Roxadustat in the treatment of anaemia in chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-inducible factor-prolyl hydroxylase inhibitor Roxadustat (FG-4592) reduces renal fibrosis in Dahl salt-sensitive rats.
Naito Y; Yasumura S; Okuno K; Asakura M; Tsujino T; Masuyama T; Ishihara M
J Hypertens; 2024 Mar; 42(3):497-505. PubMed ID: 38014420
[TBL] [Abstract][Full Text] [Related]
34. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
Locatelli F; Minutolo R; De Nicola L; Del Vecchio L
Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500
[TBL] [Abstract][Full Text] [Related]
35. HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia.
Patel VJ; Joharapurkar A; Kshirsagar SG; Patel MS; Savsani HH; Dodiya HS; Rakhasiya MH; Kajavadara C; Valani D; Jain MR
Toxicol Appl Pharmacol; 2024 Feb; 483():116832. PubMed ID: 38266872
[TBL] [Abstract][Full Text] [Related]
36. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
Wu Y; Jiang Z; You Q; Zhang X
Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
[TBL] [Abstract][Full Text] [Related]
37. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
[TBL] [Abstract][Full Text] [Related]
38. Enarodustat: First Approval.
Markham A
Drugs; 2021 Jan; 81(1):169-174. PubMed ID: 33320297
[TBL] [Abstract][Full Text] [Related]
39. Desidustat: First Approval.
Dhillon S
Drugs; 2022 Jul; 82(11):1207-1212. PubMed ID: 35834123
[TBL] [Abstract][Full Text] [Related]
40. Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
Grzeszczak W; Szczyra D; Śnit M
Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33567688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
